Page 4 - Human Pharma News Today

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer ...

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The results showed a significant reduction of albuminuria, a marker of kidney damage,2 by up to 39.5% when BI 690517 was given on top of empagliflozin, a sodium glucose ...

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,...

Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults Validated tools to […]

Boehringer Ingelheim today announced promising 14week Phase II data for BI 690517 a novel selective aldosterone synthase inhibitor ASi.

/PRNewswire/ -- Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict...

More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that using two tests can help detect it. That's why Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, now presents itself with a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners, and employees. The evolved brand includes several striking changes including the introduction of ...

Boehringer Ingelheim today announced that SPEVIGO spesolimab has been recognized as Best OrphanRare Diseases Solution of 2023 by the Galien Foundation.

SYNCHRONIZE-1, SYCHRONIZE-2, SYNCHRONIZE-CVOT will evaluate survodutide for overweight and obesity.